112
Participants
Start Date
March 2, 2021
Primary Completion Date
March 22, 2024
Study Completion Date
March 22, 2024
CVL-562 (PF-06412562) 1 mg
Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
CVL-562 (PF-06412562) 4 mg
Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
CVL-562 (PF-06412562) 15 mg
Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
CVL-562 (PF-06412562) 25 mg
Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Placebo
Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Columbia University, New York
Stony Brook University, Stony Brook
University of Pennsylvania, Philadelphia
Yale University, New Haven
Collaborators (1)
Columbia University
OTHER
University of Pennsylvania
OTHER
State University of New York Stony Brook
UNKNOWN
Cerevel Therapeutics, LLC
INDUSTRY
National Institute of Mental Health (NIMH)
NIH
Yale University
OTHER